Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
暂无分享,去创建一个
Brigitte Autran | Laurence Meyer | Asier Sáez-Cirión | Charline Bacchus | Faroudy Boufassa | Thierry Prazuck | B. Autran | C. Rouzioux | D. Costagliola | L. Meyer | O. Lambotte | A. Sáez-Cirión | C. Goujard | G. Pancino | C. Lécuroux | Dominique Costagliola | F. Boufassa | C. Bacchus | L. Hocqueloux | B. Descours | A. Venet | Cécile Goujard | Julien Guergnon | V. Avettand-Fenoel | T. Prazuck | Jean-Paul Viard | Christine Rouzioux | J. Viard | Olivier Lambotte | Pierre Versmisse | Gianfranco Pancino | Alain Venet | Laurent Hocqueloux | Adeline Melard | Véronique Avettand-Fenoel | P. Versmisse | Isabelle Girault | Camille Lecuroux | Valerie Potard | Benjamin Descours | A. Mélard | V. Potard | J. Guergnon | I. Girault | Camille Lécuroux
[1] M. Proschan,et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. , 2010, Blood.
[2] C. Rouzioux,et al. Rapid CD4+ Cell Decrease After Transient cART Initiated During Primary HIV Infection (ANRS PRIMO and SEROCO Cohorts) , 2008, Journal of acquired immune deficiency syndromes.
[3] B. Agan,et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. , 2009, The Journal of infectious diseases.
[4] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[5] Ross J. Harris,et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.
[6] Jack T Stapleton,et al. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.
[7] C. Delaugerre,et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. , 2013, The Journal of antimicrobial chemotherapy.
[8] E. Rosenberg,et al. Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.
[9] C. Rouzioux,et al. Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.
[10] A. Bergamaschi,et al. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. , 2011, Blood.
[11] Jeffrey N. Martin,et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. , 2008, The Journal of infectious diseases.
[12] E. Rosenberg,et al. Limited Durability of Viral Control following Treated Acute HIV Infection , 2004, PLoS medicine.
[13] C. Rouzioux,et al. CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory , 2011, PloS one.
[14] A. d’Arminio Monforte,et al. Treatment interruptions in HIV-infected subjects. , 2006, The Journal of antimicrobial chemotherapy.
[15] James M Robins,et al. When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries , 2011, Annals of Internal Medicine.
[16] Asier Sáez-Cirión,et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.
[17] Eric Delwart,et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection , 2002, AIDS.
[18] M. Rosińska,et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2012, Archives of internal medicine.
[19] F. Marincola,et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[20] A. Sáez-Cirión,et al. Ex vivo T cell–based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses , 2010, Nature Protocols.
[21] Thierry Prazuck,et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection , 2010, AIDS.
[22] C. Rouzioux,et al. LTR Real-Time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants Born to Seropositive Mothers Treated in HAART Area ( ANRS CO 01 ) , 2008 .
[23] Lei Wang,et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. , 2006, The Journal of infectious diseases.
[24] Matthew C Strain,et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.
[25] R. Sékaly,et al. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV , 2011, Current opinion in HIV and AIDS.
[26] J. Brenchley,et al. Low levels of SIV infection in sooty mangabey central-memory CD4+ T-cells is associated with limited CCR5 expression , 2011, Nature Medicine.
[27] J. Farrar,et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. , 2011, AIDS.
[28] Steven G. Deeks,et al. HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control , 2008, Journal of Virology.
[29] G. Carcelain,et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] J J Goedert,et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. , 2001, The New England journal of medicine.
[31] S. Lewin,et al. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? , 2011, AIDS.
[32] C. Hallahan,et al. Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors , 2000, The Journal of Immunology.
[33] Mario Roederer,et al. T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.
[34] Hendrik Streeck,et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. , 2005, Blood.
[35] C. Rouzioux,et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors , 2008, AIDS.
[36] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[37] L. Meyer,et al. CD8+ T Cells Specific for EBV, Cytomegalovirus, and Influenza Virus Are Activated during Primary HIV Infection1 , 2004, The Journal of Immunology.
[38] L. Meyer,et al. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters , 2005, AIDS.
[39] C. Rouzioux,et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy , 2001, AIDS.
[40] Mario Roederer,et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. , 2010, The Journal of infectious diseases.
[41] P. Easterbrook,et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[42] Avettand‐Fènoël Véronique,et al. LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .
[43] J. Goedert,et al. HLA-B*35-Px–mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses , 2009, The Journal of experimental medicine.
[44] T V Perneger,et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia , 2000, AIDS.
[45] C. Rouzioux,et al. Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses1 , 2009, The Journal of Immunology.
[46] C. Rouzioux,et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.